Becton, Dickinson and Company (BDX) is set to announce its fiscal third-quarter earnings for 2025, with analysts expecting a profit of $3.42 per share, down 2.3% from the year-ago quarter. The global medical technology giant is valued at $52.3 billion and offers solutions to advance medical research, enhance disease diagnosis, and improve medication management. However, BDX stock has underperformed in the past year, down 22.6%, due to a software recall in its Alaris infusion pump systems. Despite this, analysts hold a reasonably bullish outlook on the stock with an average price target of $213.71.

Read more at Yahoo Finance: What to Expect From Becton, Dickinson and Company’s Report